Compugen (CGEN) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Compugen Reports First Quarter 2022 Results
May 16, 2022 7:00 AM EDTTriple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responsesCOM701, a unique check point inhibitor, with potential to recruit additional T cells to the TMECOM902 has the potential to be a best-in-class anti-TIGIT antibodyOn track to deliver clinical data from the cohort expansion study of COM701/nivolumab in MSS CRC in Q4 2022Enrollment continues in the Phase 1 clinical studies for COM701 and COM902Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis... More
